Global Markets Direct’s, 'Orthostatic Intolerance - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Orthostatic Intolerance, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Orthostatic Intolerance. Orthostatic Intolerance - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Orthostatic Intolerance. - A review of the Orthostatic Intolerance products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Orthostatic Intolerance pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Orthostatic Intolerance. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Orthostatic Intolerance pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Orthostatic Intolerance - Pipeline Review, H2 2013 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 3 Introduction 4 Global Markets Direct Report Coverage 4 Orthostatic Intolerance Overview 5 Therapeutics Development 6 Pipeline Products for Orthostatic Intolerance - Overview 6 Pipeline Products for Orthostatic Intolerance - Comparative Analysis 7 Orthostatic Intolerance - Therapeutics under Investigation by Universities/Institutes 8 Orthostatic Intolerance - Pipeline Products Glance 9 Clinical Stage Products 9 Orthostatic Intolerance - Products under Investigation by Universities/Institutes 10 Orthostatic Intolerance - Therapeutics Assessment 11 Assessment by Monotherapy Products 11 Assessment by Target 12 Assessment by Mechanism of Action 14 Assessment by Route of Administration 16 Assessment by Molecule Type 17 Assessment by Therapeutic Class 18 Drug Profiles 20 acetazolamide sodium - Drug Profile 20 Product Description 20 Mechanism of Action 20 RandD Progress 20 atomoxetine hydrochloride - Drug Profile 21 Product Description 21 Mechanism of Action 21 RandD Progress 21 entacapone - Drug Profile 22 Product Description 22 Mechanism of Action 22 RandD Progress 22 mecamylamine hydrochloride - Drug Profile 23 Product Description 23 Mechanism of Action 23 RandD Progress 23 memantine hydrochloride - Drug Profile 24 Product Description 24 Mechanism of Action 24 RandD Progress 24 isosorbide dinitrate - Drug Profile 25 Product Description 25 Mechanism of Action 25 RandD Progress 25 Appendix 26 Methodology 26 Coverage 26 Secondary Research 26 Primary Research 26 Expert Panel Validation 26 Contact Us 27 Disclaimer 27
List of Tables
Number of Products under Development for Orthostatic Intolerance, H2 2013 6 Number of Products under Development for Orthostatic Intolerance - Comparative Analysis, H2 2013 7 Number of Products under Investigation by Universities/Institutes, H2 2013 8 Comparative Analysis by Clinical Stage Development, H2 2013 9 Products under Investigation by Universities/Institutes, H2 2013 10 Assessment by Monotherapy Products, H2 2013 11 Number of Products by Stage and Target, H2 2013 13 Number of Products by Stage and Mechanism of Action, H2 2013 15 Number of Products by Stage and Route of Administration, H2 2013 16 Number of Products by Stage and Molecule Type, H2 2013 17 Number of Products by Stage and Therapeutic Class, H2 2013 19
List of Figures
Number of Products under Development for Orthostatic Intolerance - Comparative Analysis, H2 2013 7 Number of Products by Top 10 Target, H2 2013 12 Number of Products by Stage and Top 10 Target, H2 2013 13 Number of Products by Top 10 Mechanism of Action, H2 2013 14 Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 15 Number of Products by Top 10 Therapeutic Class, H2 2013 18 Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 19